The third quarter financial results of MaxCyte (NASDAQ: MXCT) will be revealed on Wednesday 6th November 2024. This eagerly awaited announcement is slated to occur after market close, enabling investors and market participants to gain valuable insights into the company's financial performance.
According to financial analysts on Wall Street, the establishment is likely to announce an estimated per share $0.12 loss for the quarter. Additionally, the company is anticipated to reveal a total revenue of $7.37 million during this period.
Financial experts on Wall Street have shared their predictions regarding the company's annual performance, estimating a total revenue of $36.92 million. Additionally, they are expecting the company to report loss of $0.42 per share for the full year 2024.
In the preceding quarter of the previous year, the company shared its financial results, revealing that it had loss of $0.11 per share.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $-0.09 | +10.0% | 10.43 M | +15.3% |
| Q1 2024 | $-0.09 | +18.2% | 11.34 M | +32.3% |
| Q4 2023 | $-0.05 | 0% | 15.67 M | +26.1% |
| Q3 2023 | $-0.11 | -83.3% | 8.01 M | -24.8% |
| Q2 2023 | $-0.10 | -25.0% | 9.04 M | -5.9% |
| *Growth on year-over-year basis | ||||
The business has scheduled a conference call on 6th November 2024 at 04:30 PM eastern time to discuss Q3 financial results.
MaxCyte (MXCT) closed Friday's regular trading session at $3.77, demonstrating a 5.31 percent advance, with a volume of 367.10 thousand shares.
